The Pulmonary Protection Trial

NCT ID: NCT01614951

Last Updated: 2014-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether patients with a preoperative reduced pulmonary function have a better preserved oxygenation capacity after open heart surgery, using either pulmonary perfusion or pulmoplegia compared with TAVI and the control-group with standard ECC (Extra Corporal Circulation).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary perfusion

Group Type EXPERIMENTAL

Perfusion of the lungs

Intervention Type PROCEDURE

Pulmonary perfusion with oxygenated blood during ECC.

Pulmoplegia

Group Type EXPERIMENTAL

HTK Custodiol

Intervention Type DRUG

Pulmoplegia before ECC.

Control group

Group Type OTHER

Standard ECC

Intervention Type OTHER

ECC after standard procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Perfusion of the lungs

Pulmonary perfusion with oxygenated blood during ECC.

Intervention Type PROCEDURE

HTK Custodiol

Pulmoplegia before ECC.

Intervention Type DRUG

Standard ECC

ECC after standard procedure

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Planned and urgent surgery on legally competent patients over 18 years:

* Coronary Artery Bypass Graft Surgery
* Aortic Valve Replacement
* Coronary Artery Bypass Graft Surgery + Aortic Valve Replacement
* Transcatheter Aortic-Valve Implantation
2. Spirometry FEV1 measurement show less than or equal to 80% of the anticipated. We expect that these patients provide the largest signal with lung protective interventions in relation to lung healthy patients.

Exclusion Criteria

* Previous surgery on the heart or lungs
* Previous thoracic irradiation
* Preoperative heart failure (ejection fraction below 20%).
* Surgical demanding mitral regurgitation
* Unstable patients (heart rate above 100 and systolic blood pressure below 100 mmHg)
* Intubated patients
* Patients with an ongoing preoperative treatment with antibiotics for suspected pneumonia.
* Patients with renal insufficiency requiring hemodialysis
* Pregnant and lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lundbeck Foundation

OTHER

Sponsor Role collaborator

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Steinbruchel

Prof. dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel A. Steinbrüchel, prof.

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Thoracic Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen N, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Buggeskov KB, Sundskard MM, Jonassen T, Andersen LW, Secher NH, Ravn HB, Steinbruchel DA, Jakobsen JC, Wetterslev J. Pulmonary artery perfusion versus no pulmonary perfusion during cardiopulmonary bypass in patients with COPD: a randomised clinical trial. BMJ Open Respir Res. 2016 Sep 6;3(1):e000146. doi: 10.1136/bmjresp-2016-000146. eCollection 2016.

Reference Type DERIVED
PMID: 27651908 (View on PubMed)

Buggeskov KB, Jakobsen JC, Secher NH, Jonassen T, Andersen LW, Steinbruchel DA, Wetterslev J. Detailed statistical analysis plan for the pulmonary protection trial. Trials. 2014 Dec 23;15:510. doi: 10.1186/1745-6215-15-510.

Reference Type DERIVED
PMID: 25539792 (View on PubMed)

Buggeskov KB, Wetterslev J, Secher NH, Andersen LW, Jonassen T, Steinbruchel DA. Pulmonary perfusion with oxygenated blood or custodiol HTK solution during cardiac surgery for postoperative pulmonary function in COPD patients: a trial protocol for the randomized, clinical, parallel group, assessor and data analyst blinded Pulmonary Protection Trial. Trials. 2013 Jan 31;14:30. doi: 10.1186/1745-6215-14-30.

Reference Type DERIVED
PMID: 23363494 (View on PubMed)

Risom EC, Buggeskov KB, Mogensen UB, Sundskard M, Mortensen J, Ravn HB. Preoperative pulmonary function in all comers for cardiac surgery predicts mortalitydagger. Interact Cardiovasc Thorac Surg. 2019 Aug 1;29(2):244-251. doi: 10.1093/icvts/ivz049. Epub 2019 Mar 15.

Reference Type DERIVED
PMID: 30879046 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-006290-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

4141

Identifier Type: OTHER

Identifier Source: secondary_id

H-1-2012-0 24

Identifier Type: OTHER

Identifier Source: secondary_id

2007-58-0015.

Identifier Type: OTHER

Identifier Source: secondary_id

4141

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HF Tissue Registry
NCT02683681 ENROLLING_BY_INVITATION